Betaseron: SHR will begin in the second half of 2002 an international, blinded Phase III BEYOND trial in more than 2,000 RRMS patients evaluating 250 µg of Beta

Schering AG (SHR; FSE:SCH), Berlin, Germany
Product: Betaseron
Business: Neurological

Read the full 104 word article

How to gain access

Continue reading with a
two-week free trial.